European Commission Approves Novo Nordisk's Injectable Drug for ObesityEuropean Commission Approves Novo Nordisk's Injectable Drug for Obesity

The European Commission has approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects approximately 10 to 30 percent of adults in the European Union. International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news